Logo
AZN logo
AstraZeneca PLC
AZN
206.87 (0.87%) 1.80
Health Care
Pharmaceuticals
AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company offers Imjudo Datroway Iressa Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Farxiga Brilinta Crestor Seloken Lokelma Roxadustat Andexxa Wainua Symbicort Fasenra Pulmicort Breztri/Trixeo Saphnelo Tezspire Airsupra Ultomiris Soliris Strensiq Koselugo Kanuma Atacand Plendil Modip Splendil Munobal Flodil Komboglyze Qtern Byetta XIGDUO Accolate Accoleit Vanticon Beyfortus Synagis FluMist tixagevimab and cilgavimab and sipavibart. It also provides Bricanyl Respules Eklira Genuair/Tudorza/Bretaris Bricanyl Turbuhaler Rhinocort Bevespi Aerosphere Daliresp/Daxas Oxis Turbuhaler Breztri Aerosphere Duaklir Genuair Kavigale Evusheld Fluenz/FluMist and Voydeya. The company offers its products for ocology cardiovascular renal and metabolism respiratory & immunology vaccines and immune and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom the United States Europe and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare life sciences and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates with the potential to treat diseases across multiple indications and multiple next-generation therapies for obesity and type 2 diabetes; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.

Quality Checklist 5/8

ROIC > 10%
Debt/Equity < 1
Net Margin > 10%
Past Net Income CAGR > 0%
Est. EPS Growth > 5%
5Y Shares Out Change < 0%
Current Ratio > 1
Quick Ratio > 1
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $320.84(B)
EV: $337.90(B)
Total Equity: $48.72(B)
Earnings date: Apr-29-2026
P/E: 31.34
Forward P/E: 20.08
P/FCF: 27.26
P/S: 5.46
P/B: 6.59
EPS: $6.6
EPS (fwd): $10.3
FCF/share: $7.6
Revenue/share: $37.9
Book value/share: $31.4
ROIC: 12.5%
ROA: 8.6%
ROE: 21.7%
Debt/Equity: 0.61
Current Ratio: 0.90
Gross margin: 81.7%
Operating margin: 22.0%
Net margin: 17.4%
Dividend/share: $3.2
Div. yield: 1.55%
All Valuation Overview Growth Financials & KPIsCompetitors & Peer Comparison Ownership Tools

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$58.74(B)
Gross profit$47.97(B)
EBITDA$19.50(B)
Net income$10.22(B)
Gross margin81.7%
Operating margin22.0%
Net margin17.4%
Shares outstanding1.55(B)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$114.07(B)
Current assets$28.72(B)
Total liabilities$65.36(B)
Current liabilities$30.62(B)
Cash & Short-term inv.$5.74(B)
Long-term debt$24.71(B)
Total intangibles$59.09(B)
PP&E$14.70(B)

Cash flow (TTM)

CFOCFICFF
FCF$11.77(B)
CapEx$-2.81(B)
Dividends paid$-4.97(B)
Stock issued$40.00(M)
Stock repurchased$-521.00(M)
Stock-based comp.$660.00(M)
Debt issued$379.00(M)
Debt repaid$-2.40(B)

Per share data (TTM)

Price: $207
Revenue: $37.9 (5.5x | 18.3%) Gross profit: $30.9 (6.7x | 15.0%) Earnings: $6.60 (31.3x | 3.2%)
FCF: $7.59 (27.3x | 3.7%) Stock-based Comp.: $0.43 (486.1x | 0.2%) CapEx.: $1.81 (114.2x | 0.9%) Dividend: $3.20 (64.6x | 1.5%)
Total Assets: $73.6 (2.8x | 35.6%) Total Liabilities: $42.1 (4.9x | 20.4%) Book Value: $31.4 (6.6x | 15.2%) Cash & ST inv.: $3.70 (55.9x | 1.8%) Debt: $15.9 (13.0x | 7.7%)
Earnings FY+1: $10.3 (20.1x | 5.0%) Earnings FY+2: $11.6 (17.8x | 5.6%) Earnings FY+3: $12.7 (16.3x | 6.2%) Earnings FY+4: $13.9 (14.9x | 6.7%) Earnings FY+5: $15.2 (13.6x | 7.3%)
FCF FY+1: $6.70 (30.9x | 3.2%) FCF FY+2: $8.68 (23.8x | 4.2%) FCF FY+3: $10.3 (20.1x | 5.0%) FCF FY+4: $10.8 (19.1x | 5.2%) FCF FY+5: $11.8 (17.6x | 5.7%)

Summary

(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact